Table 3 Strongest synergisms and antagonisms of combined modification in the Trypanosoma model.
From: TIde: a software for the systematic scanning of drug targets in kinetic network models
Modification 1 | Modification 2 | Effect 1 | Effect 2 | Combined effect |
|---|---|---|---|---|
GPO c/n/u | GK c/k/n/u | ≈ -1.2 | ≈ -0.07 | ≈ -84 |
PFK k | TPI c | -0.026 | -1.48 | -90 |
PGK k | PGM c | -0.13 | -0.37 | -20 |
TPI c | GK c/k/n/u | -1.48 | ≈ 0.07 | ≈ 18.5 |
TPI c | GPO a | -1.48 | -0.04 | -16 |
GT a | PFK k | 23 | -0.026 | -90 |
GT a | PGK k | 23 | -0.13 | -12 |
HK a | PFK c | 0.6 | -9 | -90 |
- Numerical values are the relative flux reductions in
(reference flux: ≈ 90, corresponding to 1.5·10-3 
) resulting from a modification at an effective concentration of 100. The abbreviations stand for the targets (glycerol 3 phosphate oxidase (GPO), glycerol kinase (GK), phosphofructokinase (PFK), triosephosphate isomerase (TPI), phosphoglycerate kinase (PGK), and hexokinase (HK)) and the modification types (competitive (c), noncompetitive (n), uncompetitive (u), competitive for cofactors (k), and activation (a)).
(reference flux: ≈ 90, corresponding to 1.5·10-3 
) resulting from a modification at an effective concentration of 100. The abbreviations stand for the targets (glycerol 3 phosphate oxidase (GPO), glycerol kinase (GK), phosphofructokinase (PFK), triosephosphate isomerase (TPI), phosphoglycerate kinase (PGK), and hexokinase (HK)) and the modification types (competitive (c), noncompetitive (n), uncompetitive (u), competitive for cofactors (k), and activation (a)).